Lipid-based formulations of amphotericin B;Lipidowe i liposomalne formy amfoterycyny B

Mikologia Lekarska

Volumn 10, Issue 3, 2003, Pages 219-221

  Kołodziej, Tomasz ^a,b   Białynicki Birula, Rafał ^a  

^a Katedra i Klinika   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Amphotericin B; Amphotericin B colloid dispersion ABCD; Amphotericin B lipid complex ABLC; Liposomal amphotericin B; Mycological treatment

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ASPERGILLUS; BLASTOMYCES; CHILL; CLINICAL TRIAL; COLLOID; DISPERSION; DRUG FORMULATION; FEVER; HUMAN; MYCOSIS; NAUSEA; REVIEW; SIDE EFFECT; STREPTOMYCES; VOMITING;

ASPERGILLUS; BLASTOMYCES; STREPTOMYCES;

EID: 19244383543     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Beck-Sague C., Jarvis W.R.: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis., 1993, 167, 1247-1251.
2. Bennett J.E., Antifungal Agents. [w:] Gilman A.G., Rall T.W., Nies A.S.: The Pharmacological Basis of Therapeutics, 8 wyd., Pergamon Press, New York, 1990, rozdział 50.
3. Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G.: Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents. Chemother., 1990, 34, 138-8.
4. Wingard J.R., Kubilis P., Lee L., Yee G., White M., Walshe L.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspegillosis. Clin. Infect. Dis., 1999, 29, 1402-7.
5. Eriksson U., Seifert B., Schaffner A.: Comparison of effects of amphotericin B deoxycholate infused over 4 to 24 hours: randomised controlled trial. Br. Med. J., 2001, 322, 359-82.
6. Gallis H.A., Drew R.H., Pickard W.W.: Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis., 1990, 12, 308-29.
7. Andreasen S., Bartoo G., Braegger B., Sharp J., Smith T.: Amphotericin B Formulations, 2000, internet: http://pharmacy.isu.edu/~ndas/Term%20papers%202000/Amphotericin.PDF.
8. Andreasen S., Bartoo G., Braegger B., Sharp J., Smith T.: Amphotericin B Formulations, 2000, internet: http://pharmacy.isu.edu/~ndas/Term%20papers%202000/Amphotericin.PDF.
9. Dismukes W.E.: Lipid Formulations of amphotericin B, 2001, internet: www.ansorp.org/isaar/2001/blue/25.pdf
10. Wingard J.R., White M.H., Anaissie E., Raffalli J.: L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus apmhotericin B lipid complex in the empirical treatment of febrile neutropenia. Clinical Infectious Diseases, 2000, 31, 1155-1163.
11. Clark J.M., Whitney R.R., Olsen S.J., George R.J., Swerdel M.R., Kunselman L., Bonner D.P.: Amphotericin B Lipid Complex therapy of experimental fungal infections in mice. Antimicrob. Agents. Chemother., 1991, 35, 615-621.
12. Hann I.M., Stevens R.F., Pinkerton C.R., Darbyshire P.J., Gibson B.E.S., Oakhill A., Eestermans G.H.: Safety and efficacy of two dose regimens of AmBisome vesus amphotericin B as empirical antifungal treatment in neutropenic paediatric patients. 2nd International Symposium on Febrile Neutropenia 1995. Abstract.
13. Harrison L.H., Stevens D.A.: Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B sulphate colloid dispersion. Antimicrob. Agents. Chemother., 1992, 36, 486-488.
14. Arikan S., Rex J.H.: Nystatin LF. Curr. Opin. Invest. Drugs., 2001, 2,488-495.
15. Arikan S., Rex J.H.: Lipid-based antifungal agents: Current status. Curr. Pharmaceut. Des., 2001, 7, 393-415.